Develops non-invasive diagnostics to detect cancer at early stages and proprietary therapies to treat cancer.
bioAffinity Technologies, Inc. is a pioneering biotechnology firm focused on advancing non-invasive diagnostic tests and specialized cancer treatments. Founded in 2014 and headquartered in San Antonio, Texas, the company is dedicated to developing innovative solutions that improve early detection and treatment outcomes in cancer patients.
At the forefront of its offerings is CyPath lung, a cutting-edge diagnostic test specifically designed for the early detection of lung cancer. This breakthrough technology aims to detect cancer at its earliest stages, thereby enabling timely intervention and potentially improving survival rates. In addition to its diagnostic capabilities, bioAffinity Technologies is actively engaged in research to develop targeted therapies that address cancer at the cellular level.
Leveraging its expertise in biotechnology and oncology, bioAffinity Technologies is committed to making significant strides in the fight against cancer. By integrating advanced scientific research with practical diagnostic tools, the company seeks to redefine standards of care and enhance patient outcomes worldwide.